Andros-Italia, Outpatient Clinic of Ferrara, Ferrara 44121, Italy.
Asian J Androl. 2011 Nov;13(6):895-7. doi: 10.1038/aja.2011.44. Epub 2011 Jun 27.
We investigated whether letrozole (2.5 mg day(-1)) improves sperm count in non-obstructive azoospermia (NOA) patients. Four men were included in this study, and they had folliculo-stimulating hormone and other hormone levels within the normal range and no varicoceles or chromosomal aberrations. These four patients were administered letrozole for 3 months. Sperm count, testicular volume, gonadotropin, testosterone (T) and estradiol (E2) blood levels were assessed before, during and 1 week after the suspension of treatment. All patients showed spermatozoa in their ejaculate, increased gonadotropin and T levels and lower E2 levels (P<0.05 in all cases), when letrozole was administered. This suggests that letrozole treatment might improve sperm count in an NOA sub-population; however, more studies, including the proper controls, are needed to confirm its efficacy.
我们研究了来曲唑（2.5 毫克/天）是否能改善非梗阻性无精子症（NOA）患者的精子计数。本研究纳入了 4 名患者，他们的卵泡刺激素和其他激素水平在正常范围内，没有精索静脉曲张或染色体异常。这 4 名患者接受了来曲唑治疗 3 个月。在治疗开始前、治疗期间和停药后 1 周，评估了精子计数、睾丸体积、促性腺激素、睾酮（T）和雌二醇（E2）的血液水平。所有患者的精液中均出现了精子，促性腺激素和 T 水平升高，E2 水平降低（所有情况均 P<0.05），表明来曲唑治疗可能改善部分 NOA 患者的精子计数。然而，需要更多的研究，包括适当的对照，来证实其疗效。
